Genflow Biosciences Share Discussion Threads

[marmiesz] 30/5/2024 13:21

Please check your facts bri15. GENF is not an AIM stock.Marmie

[moneymunch] 30/5/2024 13:03

Just a few small profit takers that have taken the price back down, and of no concern imho....this will bounce big in June as the share accumulation by the bigger players continues, with plenty of material newsflow expected. Hold on tight for the next re-rate or two in the coming weeks. Gl :-)

[jakes114] 30/5/2024 12:41

The whole market is flaky very difficult to understand, its driving me mad

[moneymunch] 30/5/2024 07:39

Just the start of Genflow’s stellar UPside journey. Gla holders:-)

[felchandbart] 30/5/2024 07:14

Excellent news! Can see this getting a further charge on today.

[moneymunch] 30/5/2024 06:36

Sarcopenia, another area of Genflow’s pipeline that could be of huge interest to a Major Pharma JV partner. Gla :-)

27/5/24

[bri15] 30/5/2024 06:24

This and Verici DX (vrci)are going to be big money makers for shareholders,I going to be adding more funds in both today.

[moneymunch] 30/5/2024 06:23

Revatis

772 followers

April 2024

Exciting News! Collaboration Alert at Revatis!🔬

We are delighted to announce the expansion of the collaboration between #Trince and #Revatis, marking a significant milestone in our journey. Together, we are proud to introduce the first photoporation platform in Wallonia, developed as part of the Mitosir project under the "BioWin-ATMP collaborative project."

The Mitosir project is dedicated to tackling muscular mitochondrial dysfunction seen in sarcopenia, a significant health issue. For this purpose, we have joined forces with #Genflow, a distinguished industrial partner known for their expertise and intellectual property in Sirtuin peptides, which are essential for mitochondrial function and anti-aging.

We're confident this collaboration will propel research in the realm of muscle health, and we're proud to work in tandem with ULB and the Uliege to explore the fundamental aspects of this critical topic.

Keep an eye out for more thrilling updates on this project! 💪💡

#stemcells #cellgenetherapy #MuscleHealth #Research #Innovation #Revatis #Trince #Genflow #ULB #Uliege #Rise #Photoporation #MitochondrialDysfunction #Sarcopenia #Biowin #wallonierelance

............

Didier Serteyn

Professor Liege University

1d

Latest Development: In our pursuit of advancing tissue engineering and extra cellular Vesicles (exosomes) production, we're working towards a significant milestone. While our goal of harvesting 1 billion muscle derived MSCs (#revatis) from a single muscle microbiopsy (10 mg) at P3 is ambitious, we're making progress step by step.

Stay tuned for updates on our journey! #stemcells #tissueengineering #regenerativemedicine #cellandgenetherapy #equinehealth #exosomes #extracellularvesicles

[molatovkid] 30/5/2024 06:13

Damn!! This alone could be a huge market if it became as standard as a winter flu shot....whilst reducing falls and hospital treatment if the elderly can be stronger.

[moneymunch] 30/5/2024 06:02

RNS Number : 3593Q
Genflow Biosciences PLC
30 May 2024




30 May 2024



Genflow Biosciences Plc



Receipt of Grant Funding



Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce receipt of 50% of its substantial non-diluting and non-reimbursable research grant. The amount received totals €381,434 from the Government of Wallonia in Belgium's Advanced Therapy Medicinal Products (ATMPs).



Genflow, together with its partner Revatis SA, has launched a 3-year sarcopenia research program [see news release here]. The remaining funds from the grant will be disbursed over the next two years based on submitted invoices. The grant will be utilized as working capital to support the Sarcopenia project.



The Sarcopenia Project focuses on the development of muscle progenitor cells (MPCs) which will be loaded with Genflow's proprietary SIRT6 for the prevention and treatment of sarcopenia. This innovative approach aims to address the underlying causes of sarcopenia and promote muscle regeneration. Muscle progenitor cells are a type of stem cell capable of differentiating into muscle cells, playing a crucial role in muscle repair and regeneration. In sarcopenic muscles, the activity and number of MPCs decline, leading to impaired muscle regeneration. By loading MPCs with the SIRT6 gene, Genflow aims to enhance the regenerative capacity of these cells and counteract the detrimental effects of aging on muscle tissue.



Dr. Eric Leire, CEO of Genflow commented: "Sarcopenia, the age-related loss of muscle mass and function, is a significant health issue affecting older adults worldwide. Genflow aims to counteract the detrimental effects of aging on muscle tissue with our Sarcopenia program, which holds potential for significantly improving the quality of life for older adults affected by muscle loss and weakness."

[moneymunch] 29/5/2024 15:43

Perfectly poised and primed!!! Gla :-)

[moneymunch] 28/5/2024 16:09

Another great day as the re-rate continues, with a couple of chunky 600k trades that looked like sells which tempered the rise, although quickly absorbed into the ever diminishing free float as the demand for shares continues. Looking forward to the rest of the week and continued UPward momentum as we await the next UPdate or two. Gla holders...On and UP!!! :-)

[citys2874] 28/5/2024 13:39

multi-bagger OVB at this price just the beginning of the rise up great time to be in

good to see both on the leaderboard risers and rallying this afternoon

[moneymunch] 28/5/2024 09:29

Given how hot the liver space is and how compelling Sirt6's importance and influence appears to be in aging/longevity and multiple disease targets and Genflow's planned Nash trials, then the following deal announced end of April, for this early stage UK Biotech could be a high possibility for Genflow and due diligence could be in progress judging by the share accumulation. Gla holders, Exciting times!!!:-)))


German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate.

Under the drug discovery partnership, Ochre Bio will receive $35mn in upfront and near-term payments, rising to more than $1bn in payments and royalties if treatments are successfully brought through clinical trials. It is a similar milestone-based structure to many partnerships in the pharmaceutical industry.


The liver is the only organ that can regrow and repair itself and Ochre Bio will seek to develop drugs that restore this ability in diseased livers.

The company’s work to date has involved analysing thousands of donated human livers to develop an understanding of the causes of disease, and studying whether making changes to RNA — a vital molecule for translating genetic information into proteins — can extend the lifespan of transplanted livers.

“What we’re trying to do is give the liver a little nudge in the right direction to support it to regenerate,” said Quin Wills, chief scientific officer and co-founder of Ochre Bio. “What happens in a cirrhotic liver is [cells] don’t have that decision-making process any more to start dividing and restoring capacity. By changing certain ‘switches̵7;, using these RNA therapies, we help them make those decisions again.”

[moneymunch] 28/5/2024 08:20

In Eric we trust....this is just the start of Genflow’s stellar UPside journey. Gla holders:')

[moneymunch] 28/5/2024 07:46

A Major JV partner at anytime!!! On and UP!!! :-)))

[moneymunch] 28/5/2024 07:41

Same scenario if the FDA class ageing as a disease, although Genflow's cutting edge science and compelling nature of Sirt6 thought to be the most important and potent Gene associated with aging/longevity and multiple disease targets is going to attract significant interest and investment going forward. Gla :-)

[molatovkid] 28/5/2024 07:35

Let us put it this way, if longevity (which everyone on the planet has a vested interest in) takes off, we are looking at a Bitcoin, early days Internet Tech Stock situation I would say.

[moneymunch] 28/5/2024 07:34

Genflow's golden tickets are in very high demand. Gla holders, On and UP!!! :-)

[prashaprash] 26/5/2024 19:42

The potential is huge so short gains vs long run millionaire opportunities!Animal Bussiness for longevity will be huge is research gets the success! Imagine how vaccine made few Pharma companies billionaires! This has similar potential.

[moneymunch] 26/5/2024 14:02

It's all about market appreciation Marmie, which certainly appears to be on its way and so fair value on your valuation should quickly follow imho. A 12 month high would take us to £25m, in the meantime Zak Mir's charts are suggesting "3.8p by end of June, if not sooner", which would take us to the lower end of your valuation, although with potential game changing news stacking UP, Genflow’s share price and market cap could be propelled far higher. Full market appreciation of Genflow’s cutting edge science and unique position in the longevity space could potentially be transformational for all invested. Gl :-)

[marmiesz] 25/5/2024 17:23

Regardless of what might be announced, what is fair value with what GENF have at the moment? If I look at peers, I'm tempted to say (and this is a very broad valuation) between £15-25M? Opinions obviously welcome. And for the record, I'm not selling any until we reach a valuation way beyond what I have said above, Marmie

[moneymunch] 25/5/2024 07:06

Yet another 1m late reported buy from Thursday, one of the many over the last week or so, suggests big players have a significant interest in Genflow’s upside potential. Gla holders....Exciting times!!! ;-)